Oxaliplatin inhibits angiogenin proliferative and cell migration effects in prostate cancer cells

Marzo, Tiziano; Ferraro, Giarita; Cucci, Lorena Maria; Pratesi, Alessandro; Hansson, Örjan; Satriano, Cristina; Merlino, Antonello; Mendola, Diego La

doi:10.1016/j.jinorgbio.2021.111657

Cited by 13 publications

(31 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Indeed, metal binding to the m-bdnf was previously demonstrated . To this purpose, we first performed high-resolution mass spectrometry on d-bdnf (Figure A,B) and m-bdnf (Figure S3) to gain precise information on the nature of the adducts that are formed, including the binding stoichiometry. , Figure A reports the spectrum obtained for d-bdnf after 2 h of incubation with the excess of Zn 2+ and addition of 0.1% formic acid immediately before injection to enhance the ionization of the investigated molecules. We can observe a modest formation of adducts featured by one bound Zn 2+ ion.…”

Section: Resultsmentioning

confidence: 99%

“…In the second experimental set, we performed the same analysis without the addition of formic acid before injection (Figure B). In fact, a more acidic environment could perturb the coordination equilibria due to the protonation of those amino acid residues, that is, histidine. , It appears clear that the addition of the acid significantly affects the amount of the formed adducts, as the solution analyzed without formic acid displays a greater amount of mono-metalated peptides. This observation allows to surmise that the binding of the metal likely occurs at the level of the terminal His residues.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Neurotrophic Activity and Its Modulation by Zinc Ion of a Dimeric Peptide Mimicking the Brain-Derived Neurotrophic Factor N-Terminal Region

Russo

Giacomelli

Fortino

et al. 2022

ACS Chem. Neurosci.

Self Cite

View full text Add to dashboard Cite

Brain-derived neurotrophic factor (BDNF) is a neurotrophin (NT) essential for neuronal development and synaptic plasticity. Dysregulation of BDNF signaling is implicated in different neurological disorders. The direct NT administration as therapeutics has revealed to be challenging. This has prompted the design of peptides mimicking different regions of the BDNF structure. Although loops 2 and 4 have been thoroughly investigated, less is known regarding the BDNF N-terminal region, which is involved in the selective recognition of the TrkB receptor. Herein, a dimeric form of the linear peptide encompassing the 1–12 residues of the BDNF N-terminal (d-bdnf) was synthesized. It demonstrated to act as an agonist promoting specific phosphorylation of TrkB and downstream ERK and AKT effectors. The ability to promote TrkB dimerization was investigated by advanced fluorescence microscopy and molecular dynamics (MD) simulations, finding activation modes shared with BDNF. Furthermore, d-bdnf was able to sustain neurite outgrowth and increase the expression of differentiation (NEFM, LAMC1) and polarization markers (MAP2, MAPT) demonstrating its neurotrophic activity. As TrkB activity is affected by zinc ions in the synaptic cleft, we first verified the ability of d-bdnf to coordinate zinc and then the effect of such complexation on its activity. The d-bdnf neurotrophic activity was reduced by zinc complexation, demonstrating the role of the latter in tuning the activity of the new peptido-mimetic. Taken together our data uncover the neurotrophic properties of a novel BDNF mimetic peptide and pave the way for future studies to understand the pharmacological basis of d-bdnf action and develop novel BDNF-based therapeutic strategies.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Neurotrophic Activity and Its Modulation by Zinc Ion of a Dimeric Peptide Mimicking the Brain-Derived Neurotrophic Factor N-Terminal Region

Russo

Giacomelli

Fortino

et al. 2022

ACS Chem. Neurosci.

Self Cite

View full text Add to dashboard Cite

show abstract

“…ANG antagonists inhibit androgen-induced rRNA transcription and proliferation in androgen-dependent PC cells[ 19 ]. Surprisingly, using a comprehensive multi-technology approach of crystallography, spectroscopy, and spectral analysis, Marzo et al [ 20 ] demonstrated that oxaliplatin could effectively bind ANG to inhibit the proliferation and migration of the PC cell line PC-3. This finding provides another research direction for the treatment of PC with oxaliplatin.…”

Section: Discussionmentioning

confidence: 99%

Prostate-specific antigen reduction after capecitabine plus oxaliplatin chemotherapy: A case report

Zou¹,

Shen²,

Guo³

et al. 2023

World J Clin Cases

View full text Add to dashboard Cite

BACKGROUND Prostate cancer (PC) is currently the most common malignant tumor of the genitourinary system in men. Radical prostatectomy (RP) is recommended for the treatment of patients with localized PC. Adjuvant hormonal therapy (AHT) can be administered postoperatively in patients with high-risk or locally advanced PC. Chemotherapy is a vital remedy for castration-resistant prostate cancer (CRPC), and may also benefit patients with PC who have not progressed to CRPC. CASE SUMMARY A 68-year-old male was admitted to our hospital because of urinary irritation and dysuria with increased prostate-specific antigen (PSA) levels. After detailed examination, he was diagnosed with PC and treated with laparoscopic RP on August 3, 2020. AHT using androgen deprivation therapy (ADT) was performed postoperatively because of the positive surgical margin, extracapsular extension, and neural invasion but lasted only 6 mo. Unfortunately, he was diagnosed with rectal cancer about half a year after self-cessation of AHT, and was then treated with laparoscopic radical rectal resection and adjuvant chemotherapy using the capecitabine plus oxaliplatin (CapeOx) regimen. During the entire treatment process, the patient's PSA level first declined significantly after treatment of PC with laparoscopic RP and ADT, then rebounded because of self-cessation of ADT, and finally decreased again after CapeOx chemotherapy. CONCLUSION CapeOx chemotherapy can reduce PSA levels in patients with high-risk locally advanced PC, indicating that CapeOx may be an alternative chemotherapy regimen for PC.

show abstract

“…We have recently shown that oxaliplatin, a third-generation platinum with a 1,2-diaminocyclohexane (DACH) carrier ligand, can bind angiogenin (Ang). 23 Ang is particularly overexpressed in prostate cancer 24 and its concentration positively correlates with the evolution of prostatic epithelial cells from benign to metastatic invasive progression. 25 Hormonal refractory prostate cancer patients showed the highest Ang levels.…”

Section: Introductionmentioning

confidence: 99%

Cisplatin binding to angiogenin protein: new molecular pathways and targets for the drug's anticancer activity

et al. 2023

Self Cite

View full text Add to dashboard Cite

show abstract

Oxaliplatin inhibits angiogenin proliferative and cell migration effects in prostate cancer cells

Cited by 13 publications

References 43 publications

Neurotrophic Activity and Its Modulation by Zinc Ion of a Dimeric Peptide Mimicking the Brain-Derived Neurotrophic Factor N-Terminal Region

Neurotrophic Activity and Its Modulation by Zinc Ion of a Dimeric Peptide Mimicking the Brain-Derived Neurotrophic Factor N-Terminal Region

Prostate-specific antigen reduction after capecitabine plus oxaliplatin chemotherapy: A case report

Cisplatin binding to angiogenin protein: new molecular pathways and targets for the drug's anticancer activity

Contact Info

Product

Resources

About